论文部分内容阅读
美国FDA于2014年1月8日批准Farxiga(dapaglifozin)片剂用于治疗成人2型糖尿病,主要适用于2型糖尿病患者结合饮食和锻炼改善血糖控制。全美国大约有2 400万人患有2型糖尿病,在所有糖尿病患者中占90%以上。血糖水平过高会引发严重并发症,包括心脏疾病、失明、神经损伤和肾损伤等。Farxiga是一种钠-葡萄糖协同转运蛋白2(sodium-glucose co-transporter 2,SGLT2)抑制剂,其作用机制是阻断
The FDA approved Farxiga (dapaglifozin) tablets for the treatment of type 2 diabetes in adults on January 8, 2014 and is primarily intended for improving glycemic control in people with type 2 diabetes by combining diet and exercise. Approximately 24 million people across the United States have type 2 diabetes, accounting for more than 90% of all those with diabetes. High blood sugar levels can cause serious complications, including heart disease, blindness, nerve damage and kidney damage. Farxiga is a sodium-glucose co-transporter 2 (SGLT2) inhibitor whose mechanism of action is to block